The basic leucine zipper transcription factor CCAAT/enhancer binding protein alpha (CEBPA) codes for a critical regulator during neutrophil differentiation. Aberrant expression or function of this protein contributes to the development of acute myeloid leukemia (AML). In this study, we identified two novel unrelated CEBPA target genes, the glycolytic enzyme hexokinase 3 (HK3) and the krüppel-like factor 5 (KLF5) transcription factor, by comparing gene profiles in two cohorts of CEBPA wild-type and mutant AML patients. In addition, we found CEBPA-dependent activation of HK3 and KLF5 transcription during all-trans retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL) cells. Moreover, we observed direct regulation of HK3 by CEBPA, whereas our data suggest an indirect regulation of KLF5 by this transcription factor. Altogether, our data provide an explanation for low HK3 and KLF5 expression in particular AML subtype and establish these genes as novel CEBPA targets during neutrophil differentiation.
T he CCAAT/enhancer binding protein alpha (CEBPA) is a master regulator of myeloid differentiation that drives hematopoiesis towards the granulocytic lineage 1 . The relevance of CEBPA in the maintenance of myeloid lineage is underlined by the fact that Cebpa-null mice lack the production of neutrophils and eosinophils 2 . Not surprisingly, CEBPA functions are frequently disrupted in particular subtypes of acute myeloid leukemias (AML), thereby contributing to the differentiation arrest seen in AML blast cells. Several groups reported aberrant CEBPA function due to intragenetic mutations in 5-10% of AML patients (10-19% in normal karyotype-AML) (Reviewed in [3] [4] [5] [6] ). Mutations in the CEBPA gene predominantly cause either a frame-shift at the N-terminus resulting in the truncated CEBPA isoform p30 with dominant negative function, or disrupt the basic zipper region at the C-terminus causing weakened DNA-binding (Reviewed in 7, 8 ). Furthermore, most AML patients harbor CEBPA mutations on both alleles and these bi-allelic CEBPA mutated patients have a favorable clinical outcome as compared to CEBPA-wild-type or patients with a mono-allelic mutation (Reviewed in 5, 6 ). Lastly, transcriptional repression mediated by leukemic fusion proteins or epigenetic alterations such as aberrant promoter hypermethylation further leads to low CEBPA expression in some AML patients 9 . Our group recently reported a functional role for hexokinase 3 (HK3) and Krüppel-like factor 5 (KLF5) in the pathogenesis of AML 10, 11 . HK3 (ATP:D-hexose 6-phosphotransferase) is a glycolytic enzyme most frequently expressed in myeloid cells and represents the dominant hexokinase in granulocytes accounting for 70-80% of total hexokinase activity 10, 12 . We identified HK3 as a direct target of the transcription factors PU.1 and oncogenic fusion protein PML-RARA in acute promyelocytic leukemia (APL) characterized by the t(15;17) translocation. Inhibition of HK3 impairs neutrophil differentiation of APL cells and promotes cell death upon anthracycline treatment. We found significantly reduced HK3 expression not only in APL but also in other AML subtypes suggesting that additional mechanisms responsible for low HK3 levels in AML are operative 10 . We and others found that members of the Krüppel-like factor (KLF) family are often deregulated in primary AML patient samples 11 . The KLF transcription factor family is composed of 17 members involved in diverse functions such as proliferation, self-renewal, differentiation and apoptosis 13 . Among the different KLFs inhibited in AML, KLF5 was found to be essential for granulocytic differentiation 11, 14 . Low KLF5 expression in AML can partially be . Still unclear is how KLF5 is transcriptionally regulated during granulocytic differentiation.
In this study we describe two novel CEBPA target genes, the glycolytic enzyme HK3 and the transcription factor KLF5, both of which are significantly downregulated in CEBPA-mutated AML patients.
Results
Low HK3 and KLF5 expression is associated with CEBPA-mutated AML. CEBPA is a master regulator of myeloid differentiation, whose expression peaks in the granulocyte-monocyte progenitor cell stage, and diminishes during terminal granulocyte differentiation 3 . Most importantly, in different AML subtypes CEBPA expression or function is inhibited by a variety of mechanisms 3, 5, 6 . In an attempt to test whether HK3 and KLF5, two genes with a recently discovered role in APL differentiation 10, 11, 14 , are novel CEBPA target genes, we compared their expression in a total of 90 CEBPA-mutated or CEBPA wild-type AML patients. HK3 and KLF5 were below the detection limit in 11 and 16 AML patient samples, respectively. We compared HK3 mRNA expression in CD34 1 samples (n 5 4) to 74 CEBPA-wt and 5 CEBPA-mutated AML samples. KLF5 expression in 4 CD34 1 samples was compared to 70 CEBPA-wt and 4 CEBPA-mutated AML samples. A detailed analysis of HK3 and KLF5 mRNA levels in primary AML (FAB M0-M7) patient samples revealed a significantly lower expression of HK3 and KLF5 in CEBPA-mutated as compared to CEBPA wild-type AML samples (p , 0.01) (Figure 1a-b) . As seen for other CEBPA target genes identified by screening AML patient cohorts, our results suggest that disrupting CEBPA function impairs HK3 and KLF5 expression 15 . Next, we confirmed that HK3 and KLF5 expression is significantly lower in CEBPA-mutated, but not CEBPA wild-type patients from analysis of a second AML patient cohort (n 5 154). Since these cohorts contained patients with CEBPA single (SM) or double mutations (DM), we could address whether single or double mutations alter HK3 or KLF5 expression 16 . We found that HK3 or KLF5 expression was not significantly different from patient's samples with either CEBPA SM or DM (Figure 1c-d) . Taken together, our findings indicate that loss of HK3 or KLF5 expression correlated with CEBPA mutations, irrespective of single or double CEBPA mutations, whereas enhanced expression of HK3 or KLF5 correlated with wild-type CEBPA expression.
CEBPA-dependent induction of HK3 and KLF5 during neutrophil differentiation of APL cells. To experimentally test whether loss of CEBPA mRNA alters HK3 and KLF5 expression, we knocked down CEBPA in the two APL cell line models NB4 and HT93. This was accomplished using lentiviral vectors expressing two independent short hairpin (sh)RNAs targeting the CEBPA gene. Knockdown efficiency was evaluated by qPCR and Western blotting (Figures 2a, e and f). After 4 days of treatment with 1 mM ATRA to promote neutrophil differentiation, we observed significantly reduced HK3 and KLF5 mRNA levels in the NB4 and HT93 CEBPA knockdown cell lines as compared to the control cells (Figures 2b and c) . We evaluated G-CSFR expression in CEBPA knockdown cells (Figure 2d ) to validate inhibition of ATRA-induced neutrophil differentiation, while induction of CEBPE, a direct CEBPA regulated gene 17 , was measured as an additional control start site on the HK3 and KLF5 genomic regions, respectively (Figures 3b and d) . We next asked whether CEBPA activates HK3 and KLF5 transcription from these sites using promoter reporter assays. CEBPA co-expression with the different luciferase promoter reporters resulted in a significant, dose-dependent activation of HK3 promoter A (up to 37-fold) and KLF5 (up to 11-fold) transcription, respectively (Figures 3e and g ). The HK3 promoter B containing the CEBPA binding site 12963 was only induced 1.5-fold (Supplementary Figure S2a ). To confirm the specific CEBPA-induction of the promoter activity we mutated the CEBPA binding sites on the HK3 promoter A and the KLF5 promoter. Indeed, inactivating the CEBPA binding site in the HK3 promoter significantly inhibited transcriptional inhibition (Figure 3f) . Surprisingly, however, introducing single or double CEBPA binding sites mutations in the KLF5 promoter did not attenuate transcriptional activity of the reporter construct (Supplementary Figure S2b) . (Figures 4a and b) . CEBPA transfection efficiency was assessed by qPCR and Western blotting (Figure 4d and e). In addition, induction of the direct CEBPA target CEBPE was measured as a positive control of CEBPA activity ( Figure 4c ). Next, we used K562 leukemic cell lines expressing 4-OHT inducible fulllength CEBPA (CEBPA-p42-estrogen receptor (ER)), a truncated isoform (CEBPA-p30-ER), or a p42 isoform with a mutation preventing interaction with E2F and neutrophil differentiation (CEBPA-BRM2-ER). After 24 h of 4-OHT treatment, we observed a significant 2.5-fold transcriptional activation of KLF5 (p , 0.05) upon CEBPA-p42-ER activation only, but not in ER control, nor in CEBPA-p30-ER, or mutated CEBPA-BRM2-ER activated K562 cells (Figure 4f ), suggesting that induction of KLF5 is a specific function of the full length CEBPA p42 isoform. Interestingly, HK3 mRNA was not detectable in K562 cells indicating that different HK isoforms may be active in these cells. Induction of CEBPE was measured as a positive control (Figure 4g ). Altogether, our findings demonstrate that CEBPA is a crucial positive regulator of HK3 and KLF5 during granulocytic differentiation. Discussion Reduced CEBPA expression or loss of function mutations are commonly observed in AML suggesting that the deregulation of CEBPA function is a major event in the development of AML [18] [19] [20] . Identifying new CEBPA target genes and associated CEBPA-dependent pathways in myeloid differentiation may provide novel insights into the differentiation block as well as into ancillary cellular functions found in AML. Interestingly, CEBPA has been described as a pivotal regulator of various metabolic processes in different cell types 21 . Nevertheless, whether CEBPA regulates metabolic activity in myeloid cells is of yet unclear. Our findings now link CEBPA to glycolysis via direct positive regulation of the glycolytic enzyme HK3. We have previously shown that HK3 expression is repressed in AML, particularly in APL, where low HK3 levels are the result of PML-RARA repression and low expression of its positive regulator PU.1 10 . Our results demonstrate that CEBPA is an additional critical regulator of HK3 expression in AML and during neutrophil differentiation of APL cells. Furthermore, our findings show that the lowest HK3 expression is found in CEBPA mutated patients and may contribute to the differentiation block in this AML subtype.
In general, AML is defined by a block in differentiation and an increased proliferation of immature myeloid progenitors 18 . Additionally, loss of CEBPA-mediated cell-cycle arrest is crucial for the development of AML 15, 22, 23 . Since KLF5 regulates genes involved in cell cycle regulation and apoptosis, it may represent a relevant downstream effector of CEBPA-induced cell cycle arrest (reviewed in 24 ). In the myeloid lineage, KLF5 induces differentiation and functions as a tumor suppressor and its low expression in AML is partially explained by epigenetic silencing 11, 14, 25 . Importantly, low KLF5 expression is associated with poor overall survival 26 . In this study, we suggest an additional mechanism for low KLF5 levels in AML that is loss of positive regulation of KLF5 due to impaired CEBPA function. Since mutating the CEBPA binding sites in the KLF5 promoter constructs did not change the responsiveness of these reporters to CEBPA expression, CEBPA may indirectly activate KLF5 transcription. The KLF5 promoter lacks a TATA box, but contains a GC-rich region that is activated by the transcription factor Sp1 27 . Moreover, CEBPA can functionally interact with Sp1, e.g. in regulating the CD11c integrin gene 28 . We propose, that CEBPA induces KLF5 transcription, similarly to CD11c regulation, via Sp1. In conclusion, we identified HK3 and KLF5 as novel CEBPAregulated genes in AML and during APL differentiation underlining their tumor suppressor function in AML as well as their role in granulopoiesis.
Methods
Patient samples, cell lines and cell culture conditions. Fresh leukemic blast cells from untreated AML patients at diagnosis obtained at the Inselspital Bern (Switzerland) were classified according to the French-American-British (FAB) classification and cytogenetic analysis. All leukemic samples displayed a blast count of .90% after separation of mononuclear cells using a Ficoll gradient (Lymphoprep TM , Axon Lab AG, Switzerland) as described previously 10, 11 . PBMC and granulocytes obtained from normal, healthy donors were isolated using a Ficoll gradient.
The human acute promyelocytic leukemia (APL) cell lines NB4 and HT93 were maintained in RPMI-1640 (Sigma-Aldrich) with 10% fetal calf serum (FCS, Biochrom, AG), 50 U/mL penicillin and 50 mg/mL streptomycin (Sigma-Aldrich) in a 5% CO 2 -95% air humidified atmosphere at 37uC.
For differentiation experiments, NB4 cells were seeded at a density of 0.2 3 10 6 /ml and treated with 1 mM all-trans retinoic acid (ATRA, dissolved in DMSO, Sigma Aldrich) as indicated. Successful neutrophil differentiation was assessed by light microscopy using May-Grünwald-Giemsa (Merck, Darmstadt, Germany) stained cells and by surface expression of the differentiation marker CD11b (Immunotools). Briefly, 5 3 10 5 cells were collected, washed, and incubated with monoclonal mouse phycoerythrin (PE)-labeled anti-human-CD11b for 20 min at 4uC. Fluorescence intensity was then measured by a FACS Calibur flow cytometer (Becton Dickinson, Basel, Switzerland) and analyzed using FlowJo Software.
K562-CEBPA-p42-ER, K562-CEBPA-p30-ER, K562-CEBPA-BRM2-ER and K562-ER were kindly provided by Prof. G. Behre and were maintained in RPMI-1640 supplied with 10% fetal calf serum (FCS), 50 U/mL penicillin and 50 mg/mL streptomycin in a 5% CO 2 -95% air humidified atmosphere at 37uC. K562 CEBPA-ER cells were differentiated as described 15 by addition of 5 mM 4-OHT (Sigma-Aldrich). Human HK3 and KLF5 promoter reporter assays and mutagenesis. Two HK3 promoter regions and one KLF5 promoter region containing the CEBPA binding sites were PCR amplified from genomic DNA of NB4 APL cells using proof reading Pfu DNA polymerase (Promega, Dübendorf, Switzerland) and cloned into the pGL4.10-basic vector (Promega). All mutants were introduced using the QuickChange sitedirected mutagenesis system (Agilent, CA, USA) according to the manufacturer's instructions. Promoter transactivation assays were performed as previously described 10 . Briefly, H1299 cells were transiently transfected with 40 ng of the promoter reporter constructs together with pcDNA3.1 empty or CEBPA expression vector. The promoter activity was measured using the Dual-Luciferase Reporter Plasmid System (Promega) and is shown as relative light units (RLU) relative to pcDNA3.1 control transfected cells.
Chromatin immunoprecipitation (ChIP
TaqMan Low Density Array (LDA) and real-time quantitative reverse transcription PCR (qPCR). RNA extraction, RT-PCR and LDA measurements, as well as data analysis were done as described 10, 11 . Total RNA was extracted using the RNeasy Mini Kit and the RNase-Free DNase Set according to the manufacturer's protocol (Qiagen, Hombrechtikon, Switzerland). Total RNA was reverse transcribed using random primers (Roche Diagnostics) and M-MLV reverse transcriptase (Promega). PCR and fluorescence detection were performed using the ABI PRISMH 7500 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). Data represent log 2 expression levels and the measured cycle threshold (Ct) values were normalized to the expression levels of the housekeeping genes HMBS and ABL1.For quantification of KLF5, CEBPA, CEBPE and G-CSFR mRNA in human cells we used TaqmanH Gene Expression Assays Hs00156145_m1, Hs00269972_s1, Hs00357657_m1, and Hs00167918_m1, (Applied Biosystems), respectively. HMBS as well as ABL-1 primers and probes have been previously described 10, 11 .
Cell lysate preparation and Western blotting. Whole cell extracts were prepared using RIPA lysis buffer supplemented with 8 M UREA according to the protocol found at www.abcam.com. 40-60 mg total protein was loaded on a 10% or 12% denaturing polyacrylamide gel. Blots were incubated with the primary antibodies in TBS 0.05% Tween-20/5% milk overnight at 4uC, incubated with secondary antimouse or -rabbit antibody at 155-10,000 for 1 h at room temperature, and analyzed using the Odyssey infrared imaging system detection (Li-Cor Biosciences). Primary antibodies used were anti-CEBPA (Abcam) 15500 and anti-GAPDH (Millipore) 1559000. Secondary antibodies used were goat anti-rabbit IRDye H 800CW and goat anti-mouse IR Dye H 680LT (Li-Cor Biosciences).
Transient transfection. HT93 cells were transiently transfected using a cell nucleofector kit (Amaxa Biosystems) according to the manufacturer's instructions. Briefly, the cells were washed in PBS and then resuspended in nucleofector solution to a final concentration of 2 3 10 6 cells per 100 ml each. Afterwards, the cell suspension was mixed with plasmid DNA pcDNA3.1 either empty, as a negative control, or expressing CEBPA, using the program X-01 and incubated at 37uC and 5% CO 2 for 24 h.
Lentivirus preparation and transduction of target cells. pLKO.1-puro lentiviral vectors expressing shRNAs targeting CEBPA (shCEBPA_1: NM_004364.2-171s1c1 or shCEBPA_2: NM_004364.2-1335s1c1) or the control vector (SHC002) were purchased from Sigma-Aldrich. All vectors contain a puromycin antibiotic resistance gene for selection of transduced mammalian cells. Lentivirus production and transduction were done as described 10, 11 . Transduced HT93 and NB4 cells were selected with 1.5 mg/ml puromycin for 4 days and knockdown efficiency was validated by qPCR.
Statistical analysis. Nonparametric Mann-Whitney-U (MWU) tests were applied to compare the difference between two groups using GraphPad Prism 4 software (Graph Pad Software, San Diego, CA). P-values , 0.05 were considered statistically significant. HK3 and KLF5 promoter regions were retrieved from an online database (www.ncbi.nlm.nih.gov), while the putative CEBPA binding sites were predicted by MatInspector (www.genomatix.de).
